Power management for irritable bowel syndrome
https://doi.org/10.31146/1682-8658-ecg-182-10-112-122
Abstract
A large number of scientifi c studies are devoted to the role of diet in the treatment of irritable bowel syndrome (IBS). A signifi cant proportion of patients associate the appearance of the IBS symptoms with the intake of certain foods. Many medical communities have recognized nutrition management as an important tool in treating the disease. The article discusses the existing dietary approaches in the management of patients with IBS based on generalized data available in the modern literature. An assessment of the nature and nutrition and identifi cation of the most common types of food intolerance are considered as a “fi rstling” approach. When IBS symptoms persist, consideration should be given to applying extended recommendations such as a low-FODMAP diet. The purpose of the low-FODMAP diet is to sequentially identify specifi c triggers to control disease symptoms.
About the Authors
O. V. Gaus
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Cand. Sci. (Med.), Associate Professor of the Department of Faculty Therapy, Occupational Diseases
Scopus Author ID: 56598554900
12 Lenina street, 644099 Omsk, Russia
M. A. Livzan
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
D. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Therapy, Occupational Diseases
Scopus Author ID: 24341682600
12 Lenina street, 644099 Omsk, Russia
D. V. Popello
Federal State Educational Establishment of Higher Education Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
4th year student of the Faculty of Medicine
12 Lenina street, 644099 Omsk, Russia
References
1. Schmulson MJ, Drossman DA. What Is New in Rome IV. J. Neurogastroenterol. Motil. 2017, vol. 23, no. 2, pp. 151–163.
2. Ivashkin V. T., Shelygin Yu.A., Baranskaya Y. K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76–93. (In Russ.) https://doi.org/10.22416/1382–4376–2017–27–5–76–93
3. Gaus O. V., Livzan M. A. SRK: Chto mi znaem o simptomah segodnya [IBS: what do we know about the symptoms to day?]. Consilium Medicum. 2019, vol. 21, no. 8, pp. 42–48.
4. Mayev I. V., Tcheremushkin S. V., Kucheryavii Yu. A. Rimskiyekriterii IV: O roli vistceral’noi giperchuvst-vitel’nosti i sposobah yeye korrekcii [Rome IV: On the role of visceral hypersensitivity and how to correct it.]. Moscow. Prima Print, 2016, 64 p.
5. Kostenko M. B., Livzan M. A. Mehanizm razvitiya sindroma razdrazhennogo kishechnika [Mechanisms for the development of irritable bowel syndrome]. Sibirskii zhurnal gastroenterologii I gepatologii = Siberian Journal of Gastroenterology and Hepatology.2000, no. 10, 32 p.
6. Algera J., Colomier E., Simren M. The dietary management of patients with irritable bowel syndrome: a narrative review of the existing and emerging evidence. Nutrients. 2019, no. 11, pp. 2162–2184.
7. Livzan M. A., Gaus O. V., Turchaninov D. V., Popello D. V. Abdominal Pain Syndrome in Youth: Prevalence and R isk Factors. Experimental and Clinical Gastroenterology. 2019;1(10):12–17. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-170–10–12–17
8. Yao C. K., Gibson P. R., Shepherd S. J. Design of clinical trialsevaluating dietary interventions in patients with functional gastrointestinal disorders. Am. J. Gastroenterol. 2013, no. 108, pp. 748–758.
9. Gaus O. V., Livzan M. A., Osipenko M. F. Irritable bowel syndrome: how to a voidmistakes? Farmateka. 2020, vol. 27, no. 2, pp. 75–79. DOI: https://dx.doi.org/10.18565/pharmateca.2020.2.75–79
10. Livzan M. A., Osipenko M. F. Overlap-syndrome of functional diseases of the digestive tract. RMJ. 2012, vol. 20, no. 15, pp. 768–770.
11. Jones V. A., McLaughlan P., Shorthouse M., Workman E., Hunter J. O. Food in to lerance: A major factor in the pathogenesis of irritable bowel syndrome. Lancet. 1982, no. 2, pp. 1115–1117.
12. Nanda R., James R., Smith H., Dudley C. R., Jewell D. P. Food in to lerances and irritable bowel syndrome. Gut. 1989, no. 30, pp. 1099–1104.
13. Zwetchkenbaum B., Burakoff R. The irritable bowel syndrome and food hypersensitivity. Ann. Allergy. 1988, no. 61, pp. 47–49.
14. Biesiekierski J. R. What is gluten? J. Gastroenterol. Hepatol. 2017, no. 32, pp. 78–81.
15. Rubio-Tapia A., Malamut G., Verbeek W. H. et al. Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry. Aliment Pharmacol Ther. 2016, vol. 44, no. 7, pp. 704–714.
16. Livzan M. A., Gaus O. V., Kolbina M. V., Karasaeva F. Z., Ratnikova O. A. Celiac disease in a patient with type 1 diabetes. E x perimenta l a nd Clinica l Gastroenterology. 2019;(9):107–112. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-169–9–107–112
17. Aziz I., Trott N., Briggs R. et al. Ecacy of a Gluten-Free Diet in Subjects With Irritable Bowel SyndromeDiarrhea Unaware of Their HLA-DQ2/8 Genotype. Clin. Gastroenterol. Hepatol. 2016, no. 14, pp. 696–703.
18. Biesiekierski J. R., Iven J. Non-coeliac gluten sensitivity: piecing the puzzle together. United European Gastroenterol. J.2015, no.3, pp. 160–165.
19. Makharia A., Catassi C., Makharia G. K. The Overlap between Irritable Bowel Syndrome and Non-Celiac Gluten Sensitivity: A Clinical Dilemma. Nutrients. 2015, no. 7, pp. 10417–10426.
20. Junker Y., Zeissig S., Kim S. J. et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J. Exp. Med. 2012, no.209, pp. 2395–2408.
21. Deng Y., Misselwitz B., Dai N., Fox M. Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. Nutrients.2015, no.7, pp. 8020–8035.
22. Swallow D. M. Genetics of lactase persistence and lactose intolerance. Ann. Rev. Genet. 2003, no. 37, pp. 197–219.
23. Talley N. J. Allergies and irritable bowel syndrome. Gastroenterol. Hepatol. 2020, vol. 15, no. 11, pp. 619–621.
24. Global Practice Guidelines of the World Gastroenterological Organization. Diet and intestines. 2018. Access mode: https://www.worldgastroenterology.org/UserFiles/file/guidelines/diet-and-the-gut-russian.pdf
25. Akhmedov V. A., Orlov I. N., Gaus O. V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapiya – Therapy. 2017, no. 3 (13), pp. 49–55.
26. O’Keeffe M. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol. Motil. 2018, vol. 30, no 1, e13154.
27. Szilagyi A., Ishayek N. Lactose Intolerance, Dairy Avoidance, and Treatment Options. Nutrients.2018, no. 10, pp. 1–30.
28. Fassio F., Facioni M. S., Guagnini F. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients. 2018, no. 10, pp. 1–12.
29. Dionne J., Ford A. C., Yuan Y. et al. Systematic Review and Meta-Analysis Evaluating the Ecacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018, no. 113, pp. 1290–1300.
30. Zhao J., Zheng X., Chu H. et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphicoro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol. Motil. 2014, no. 26, pp. 794–802.
31. Lewis M. J. V., Whorwell P. J. Bran: Mayirritateirritable bowel. Nutrition. 1998, no. 14, pp. 470–471.
32. Ong D. K., Mitchell S. B., Barrett J. S. et al. Manipulation of dietary short chain carbohydratesalters the pattern of gasproduction and genesis of symptoms in irritablebowel syndrome. J. Gastroenterol. Hepatol. 2010, no. 25, pp. 1366–1373.
33. Müller M., Canfora E. E., Blaak E. E. Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers. Nutrients. 2018, no. 10, pp. 1–18.
34. Moayyedi P., Quigley E. M., Lacy B. E. et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am. J. Gastroenterol.2014, no. 109, pp. 1367–1374.
35. Capili B., Anastasi J. K., Chang M. Addressing the Role of Food in Irritable Bowel Syndrome Symptom Management. J. Nurse Pract.2016, no. 12, pp. 324–329.
36. McRorie J. W. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr. Today.2015, no.50, pp. 82–89.
37. Liu J., Chey W. D., Haller E., Eswaran S. Low-FODMAP Diet for Irritable Bowel Syndrome: What We Knowand What We Have Yetto Learn. Annu. Rev. Med. 2020, no. 71, pp. 303–314.
38. Whelan K., Martin L. D., Staudacher H. M., Lomer M. C. E. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J. Hum. Nutr. Diet. 2018, vol. 31, no. 2, pp. 239–255.
39. McKenzie Y. A., Bowyer R. K., Leach H. et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults. J. Hum. Nutr. Diet. 2016, no. 29, pp. 549–575.
40. Bennet S. M. P., Böhn L., Störsrud S. et al. Multi variate model ling off a ecalbacterial profiles of patients with IBS predicts responsivenessto a dietlowin FODMAPs. Gut. 2018, no. 67, pp. 872–881.
Review
For citations:
Gaus O.V., Livzan M.A., Popello D.V. Power management for irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2020;(10):112-122. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-182-10-112-122
Views:
597
Email this article 